RxDoctor Payments Data

John Rog, MD

Family Medicine · Valrico, FLNPI 1073604518

Payments from drug & device makers

$11,544in general payments, 2019–2025

Across 663 payments — averaging $17.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$1K
  • AstraZeneca$1K
  • Pfizer$1K
  • GSK$872
  • Lilly USA, LLC$645
  • plus $5K from 45 others

What the payments were for

  • Food & beverage$11,530100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,544 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$310,123
Medicare patients
442
Services billed
6,318

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide112$204,132
EliquisApixaban142$175,261
FarxigaDapagliflozin Propanediol101$131,336
JardianceEmpagliflozin93$120,963
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$68,347
JanuviaSitagliptin Phosphate22$37,051
XareltoRivaroxaban26$30,954
TrulicityDulaglutide25$30,168
MounjaroTirzepatide20$29,792
EntrestoSacubitril/Valsartan17$27,348
JanumetSitagliptin Phos/Metformin Hcl19$26,078
Spiriva HandihalerTiotropium Bromide15$17,575
Atorvastatin Calcium1,196$9,866
Bydureon BciseExenatide Microspheres11$9,315
Repatha SureclickEvolocumab13$9,162

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,452$204,132112 claims
PfizerEliquis$1,069$175,261142 claims
AstraZenecaFarxiga$1,104$131,336101 claims
Boehringer IngelheimJardiance$170$120,96393 claims
GSKTrelegy Ellipta, Anoro Ellipta$872$74,68461 claims
MerckJanuvia, Janumet$208$63,12941 claims
Lilly USA, LLCTrulicity, Mounjaro$645$59,96045 claims
Johnson & JohnsonXarelto$45$30,95426 claims
NovartisEntresto$146$27,34817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Valrico

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →